| name | es-cushing-medical-therapy-block-aberrant-receptors-bmah |
| description | This skill suggests medical therapy to block aberrant hormone receptors for bilateral macronodular adrenal hyperplasia (BMAH) when surgery is not preferred or feasible. Consider this approach in patients with confirmed BMAH and evidence of aberrant hormone receptor expression (e.g., GIP, LH/hCG, serotonin) driving cortisol excess. |
Medical Therapy to Block Aberrant Hormone Receptors for Bilateral Macronodular Adrenal Hyperplasia
STEP 1 — Gather Information
Confirm BMAH diagnosis with bilateral adrenal nodules on CT/MRI and hormonal evidence of autonomous cortisol secretion (elevated UFC, non‑suppressible cortisol). Assess patient preference and surgical feasibility. Perform adrenal vein sampling or hormone challenge tests (meal, GIP, LH/hCG, serotonin) to identify aberrant hormone receptors driving cortisol excess.
STEP 2 — Rule In / Rule Out
Rule in aberrant hormone receptor expression if hormone challenge provokes a cortisol rise >20% or adrenal vein sampling shows receptor‑linked secretion; rule out if no such reactivity is detected.
STEP 3 — Classify or Stratify
Classify the aberrant receptor type (e.g., GIP receptor, LH/hCG receptor, serotonin receptor, adrenal androgen receptor) to guide selection of specific antagonist therapy.
STEP 4 — Decide
Initiate medical therapy targeting the identified aberrant receptor (e.g., ketoconazole or metyrapone for steroidogenesis inhibition, or receptor‑specific antagonists such as cyproheptadine for serotonin, GnRH antagonist for LH/hCG, or investigational GIP antagonist) with the goal of normalizing cortisol levels.
Clinical Guardrails / Mimics / Pitfalls
Do not use receptor‑blocking therapy when surgery is feasible and preferred; avoid in patients with known hypersensitivity to the chosen agent; monitor for adrenal insufficiency and hypocortisolism; do not rely solely on receptor blockade if cortisol remains elevated, as adjunctive steroidogenesis inhibition may be needed; avoid agents that stimulate cortisol secretion (e.g., exogenous ACTH).
Concrete Clinical Example
A 48‑year‑old woman with bilateral adrenal nodules on CT, unsuppressed cortisol, declines surgery due to cardiac risk. Adrenal vein sampling after oral GIP shows a 45% cortisol rise, indicating aberrant GIP receptor. She is started on ketoconazole 400 mg twice daily; after 3 weeks UFC falls to normal range and symptoms improve.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818
